Financial reports
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
10 Mar 20
10-Q
2019 Q3
Quarterly report
5 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
19 Mar 19
10-Q
2018 Q3
Quarterly report
6 Nov 18
Current reports
8-K
Completion of Acquisition or Disposition of Assets
28 Sep 20
8-K
Sanofi to acquire Principia Biopharma
17 Aug 20
8-K
Principia Biopharma Reports Second Quarter 2020
6 Aug 20
8-K
Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis
26 Jun 20
8-K
Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
12 Jun 20
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 20
8-K
Principia Biopharma Reports First Quarter 2020 Financial Results
6 May 20
8-K
Other Events
24 Apr 20
8-K
Principia Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results
10 Mar 20
8-K
Other Events
7 Feb 20
Registration and prospectus
15-12B
Securities registration termination
8 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Sep 20
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Sep 20
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Sep 20
POS AM
Prospectus update (post-effective amendment)
28 Sep 20
25-NSE
Exchange delisting
28 Sep 20
SC 14D9/A
Tender offer solicitation (amended)
28 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
28 Sep 20
SC 14D9/A
Tender offer solicitation (amended)
22 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
22 Sep 20
Other
EFFECT
Notice of effectiveness
30 Sep 20
EFFECT
Notice of effectiveness
15 Oct 19
CORRESP
Correspondence with SEC
10 Oct 19
CORRESP
Correspondence with SEC
9 Oct 19
UPLOAD
Letter from SEC
8 Oct 19
CT ORDER
Confidential treatment order
13 Sep 18
EFFECT
Notice of effectiveness
13 Sep 18
CERT
Certification of approval for exchange listing
12 Sep 18
CORRESP
Correspondence with SEC
11 Sep 18
CORRESP
Correspondence with SEC
11 Sep 18
Ownership
SC 13G/A
Cormorant Asset Management, LP
16 Feb 21
SC 13D/A
GLAXOSMITHKLINE PLC
1 Oct 20
4
Shawn Tomasello
28 Sep 20
4
Patrick Machado
28 Sep 20
4
Simeon George
28 Sep 20
4
Shao-Lee Lin
28 Sep 20
4
Daniel J. Becker
28 Sep 20
4
Alan Colowick
28 Sep 20
4
Stefani Wolff
28 Sep 20
4
Dolca Thomas
28 Sep 20